COVID-19 Science Update released: December 22, 2020 Edition 70

Prevention, Mitigation and Intervention Strategies


Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.external icon Polack et al. NEJM (December 10, 2020).

Key findings:

  • The Pfizer/BioNTech SARS-CoV-2 spike protein mRNA vaccine candidate BNT162b2 was 95% efficacious in preventing symptomatic COVID-19 after two doses (Figure).
    • Similar vaccine efficacy was observed by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions.
  • Participants receiving vaccine had higher rates of local reactions (pain, redness, swelling) and systemic reactions (fever, headache, muscle pain) compared with those receiving placebo.

Methods: Phase 2/3 safety and efficacy study of a SARS-CoV-2 spike protein mRNA vaccine candidate previously reported by Walsh et al.external icon was assessed for a median of two months. Healthy persons ≥16 years old were randomly assigned 1:1 to receive two intramuscular doses of 30 μg placebo (n = 21,728) or BNT162b2 (n = 21,720) 21 days apart and followed for development of symptoms in which case they underwent viral testing for SARS-CoV-2. 8183 persons were included in the reactogenicity subset. Limitations: Safety and efficacy was studied for only 2 months and only in healthy persons; did not assess efficacy in asymptomatic persons or transmission potential of vaccinated persons.

Implications: In a remarkable historical public health achievement, the FDA approvedexternal icon the first mRNA COVID-19 vaccine that was developed in record time and that achieved 95% efficacy in a large randomized trial with minimal adverse events. Implementation should follow ACIP’s interim guidance, however there remains open questions, pointed out in Callaway et alexternal icon., such as how much protection the vaccine offers, to whom, and for how long.


Note: Adapted from Polack et al. Efficacy of COVID-19 mRNA vaccine compared to placebo by cumulative incidence of COVID-19 from the time of the first dose. Second dose given at day 21. Each symbol represents a COVID-19 case; filled symbols represent severe COVID-19 cases. The inset shows the first 21-day data on an enlarged y-axis. From NEJM, Polack et al., Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. Copyright © 2020 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Analysis of measles-mumps-rubella (MMR) titers of recovered COVID-19 patients.external icon Gold et al. MBio (November 20, 2020).

Key findings:

  • There was a significant inverse correlation (rs = −0.71, p <0.001) between mumps virus IgG titers (but not measles or rubella) and COVID-19 severity among those vaccinated with the measles-mumps-rubella (MMR II) vaccine (Figure).

Methods: Retrospective descriptive analysis comparing MMR II IgG titers and COVID-19 severity in 80 participants with prior SARS-CoV-2 infection or exposure in the US, with or without prior MMR IIexternal icon vaccination. Limitations: Small sample size; no randomization of participants; limited generalizability.

Implications: A protective effect of mumps-specific antibodies could lead to new vaccination strategies for SARS-CoV-2. A large scale trialexternal icon is underway that could help shed light on whether MMR vaccines can boost the immune response and be effective in preventing SARS-CoV-2 infection.


Note: Adapted from Gold et al. Mean mumps titer values (in arbitrary units per milliliter) among the vaccinated group were compared in each of five COVID-19 severity categories based on symptom scores. Comparison of severity data were done with a Spearman’s rank correlation coefficient, with the resulting rs and p-values. Licensed under CC 4.0.

Detection, Burden, and Impact: Modeling Excess Mortality

Excess mortality reflects the full impact of the pandemic that that may go unmeasured due to undetected COVID-19 and other pandemic-related deaths.


A. All-cause excess mortality and COVID-19–related mortality among US adults aged 25-44 years, March-July 2020external icon. Faust et al. JAMA (December 16, 2020).

Key findings:

  • 76,088 persons aged 25 to 44 years died from all causes during March through July 2020; this was 11,899 more deaths (incident rate ratio 1.19, 95% CI 1.14-1.23) than expected.
    • 4,535 COVID-19 deaths accounted for 38% (95% CI 32%-48%) of the excess mortality.
    • Data are not yet available to account for the remaining excess deaths.

Methods: 2020 all-cause and COVID-19 deaths, from provisional CDC data, were compared with expected all cause deaths for 2020 (calculated from 2015-2019 US population and mortality counts). Limitations: Incomplete data due to reporting lags.


B. Impact of population growth and aging on estimates of excess U.S. deaths during the COVID-19 pandemic, March to August 2020external icon. Shiels et al. Annals of Internal Medicine (December 15, 2020).

Key findings:

  • There were 1,671,400 US deaths from March to August 2020, compared with an average 1,370,000 deaths reported during the same months from 2015-2019.
    • Of these crude excess 301,400 deaths, 173,300 (57%) were related to COVID-19.
  • After adjusting for changes in population structure, there were an estimated 217,900 excess deaths from March through August 2020, with 173,300 (80%) related to COVID-19 (Figure).
    • Diabetes, Alzheimer’s disease, and heart disease caused the most non-COVID-19 excess deaths.

Methods: Age-specific excess deaths in the US from March through August 2020 compared with 2015 to 2019 were estimated, accounting for changes in population size and age, using provisional CDC data, Underlying Cause of Death data, and U.S. Census Bureau population estimatesexternal icon. Expected deaths were the number of deaths that would have occurred in 2020 if age-specific death rates were the same as in 2015 to 2019. Limitations: Provisional data are incomplete due to reporting lags, and excess deaths are likely underestimates.


Note: Adapted from Shiels et al. Excess US total deaths, March to August 2020. Gray bars represent excess death estimates without adjustment for population changes, and black bars represent excess death estimates with adjustment for population changes. From Annals of Internal Medicine, Shiels et al., Impact of population growth and aging on estimates of excess U.S. deaths during the COVID-19 pandemic, March to August 2020. Copyright © 2020 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.

Implications for both studies (Faust et al. & Shiels et al.): After age adjustment, the majority of overall excess deaths in the U.S. in 2020 are related to COVID-19, which has impacted younger age groups as well.


Evidence of long-distance droplet transmission of SARS-CoV-2 by direct air flow in a restaurant in Koreaexternal icon. Kwon et al. Journal of Korean Medical Science (November 30, 2020).

Key findings:

  • An investigation revealed transmission of SARS-CoV-2 quickly at a distance >6 feet in a restaurant (Figure).
    • Case A overlapped with Case B, the source, for 5 minutes at a distance of 6.5 m (21 feet) (Figure).
    • Case C overlapped with Case B for 21 minutes at a distance of 4.8 m (16 feet) (Figure).
    • Only these 2 among 13 total unmasked staff and visitors were infected (attack rate 15.4%).
  • Unlike other guests, Cases A and C were in the direct line of air flow from ceiling air conditioners (maximum 1.2 m/s) from source case B (Figure).


Methods: Epidemiologic and engineering investigations were used to identify cases and understand environmental exposures in an outbreak in Korea in June 2020. Researchers assessed closed-circuit television, table locations, timeline, and movement of cases and other people in the restaurant. Air speed and direction were measured by an anemometer. Limitations: Air flow measurements were simulations.

Implications: Droplet transmission can occur at ≥6.5 feet in a short time frame with direct air flow carrying the virus. Indoor spaces should have proper ventilation as well as physical distance and mask use to prevent transmission.


Note: Adapted from Kwon et al. Schematic diagram of the outbreak restaurant equipped with ceiling-type air conditioners. The solid arrow streamlines represent the air flow directions. Curved air streamlines represent air from the ceiling air conditioners that is reflected from the wall or barrier toward the floor. The right panel shows the time of overlap of Case B with the two other cases (red dashed line). Case D was not infectious at the time of the event and was not considered in the investigation. Licensed under CC-BY.

SARS-CoV-2 infection and transmission in educational settings: A prospective, cross-sectional analysis of infection clusters and outbreaks in England.external icon Ismail et al. Lancet Infectious Diseases (December 8, 2020).

Key findings:

  • The risk of SARS-CoV-2 infection in schools was low upon re-opening, and school-based outbreaks increased as the community incidence increased (p <0.0001) (Figure).
  • Staff had a higher incidence of SARS-CoV-2 than students and most cases linked to outbreaks were in staff members.
    • Of the 55 outbreaks, staff-to-staff transmission was most common (47%), followed by student-to-staff (29%), staff-to-student (15%), and student-to-student (9%).

Methods: Single case and outbreak data from a national database of schools and childcare settings in England from June 1 to July 17, 2020 were used to assess the correlation of school infection rates with population data and community incidence. Case rates were calculated using SARS-CoV-2 RT-PCR-confirmed cases and negative binomial regression. Limitations: Generalizability; cross-sectional design shows correlation not causation.

Implications: The overall risk of SARS-CoV-2 infection among staff and students is thought to be low; however, as Flasche and Edmundsexternal icon noted, children are often asymptomatic and their cases could be missed. The strong correlation between COVID-19 outbreaks in schools and regional incidence emphasizes the importance of controlling community transmission to protect schools and allow for safe re-openings.


Note: Adapted from Ismail et al. The number of confirmed school outbreaks increased as the regional COVID-19 incidence increased. Reprinted from The Lancet Infectious Diseases, Ismail et al., SARS-CoV-2 infection and transmission in educational settings: A prospective, cross-sectional analysis of infection clusters and outbreaks in England. Copyright 2020, with permission from Elsevier.

Protection in Healthcare and Non-healthcare Work Settings


Assessing the effectiveness of using various face coverings to mitigate the transport of airborne particles produced by coughing indoorsexternal icon. Li et al. Aerosol Science and Technology (December 4, 2020).

Key findings:

  • The difference in concentrations of particles (PNC) detected when a volunteer coughed compared with background concentrations with no cough were impacted differently by various face coverings (Figure):
    • PNC increased approximately 40-fold after cough when using no covering or only a face shield.
    • PNC increased approximately 10-fold after cough using a cloth mask with or without a face shield.
    • PNC did not increase after cough when surgical masks or N95 respirators were used.
  • 6 feet of distance reduced detected PNC as well as masks (Figure).

Methods: A volunteer coughed with and without a variety of face coverings, and cough-generated PNCs ranging from 0.01 to >1.0 µm, at 1, 3, and 6 feet away, were detected by an instrument indoors and compared to background with no coughing. Limitations: A single volunteer and setting; relationship between PNC and infectious SARS-CoV-2 dose unknown.

Implications: Cloth masks alone, but not face shields, were effective at reducing respiratory droplet spread, Surgical masks or N95 respirators were much more efficient. Data support recommendations to wear masks and maintain physical distance from others to prevent SARS-CoV-2 spread.


Note: Adapted from Li et al. Background-subtracted particle number concentration (PNC) at 1, 3, and 6 feet away from a coughing volunteer under different face covering conditions. Error bars show the standard error of the mean. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared with background PNC. Figure 2, Assessing the effectiveness of using various face coverings to mitigate the transport of airborne particles produced by coughing indoors. Li et al. Aerosol Science and Technology, reprinted by permission of The American Association for Aerosol Research,



The following paper evaluates if baricitinib, an inhibitor of immune and inflammatory responses given orally to treat moderate-to-severe rheumatoid arthritis, provides added benefit for COVID-19 treatment.

Baricitinib plus remdesivir for hospitalized adults with COVID-19.external icon Kalil et al. NEJM (December 11, 2020).

Key findings:

  • COVID-19 patients receiving remdesivir (RDV) plus baricitinib compared with RDV plus placebo (control group) had:
    • Reduced recovery time (7 vs 8 days; RR 1.16, 95% CI 1.01-1.32, p = 0.03) (Figure).
    • Accelerated clinical improvements (OR 1.3, 95% CI 1.0-1.6).
    • Lower mortality at day 28 (5.1% vs.7.8%, HR 0.65, 95% CI 0.39-1.09).
    • Lower incidence of serious or nonserious adverse events (p = 0.003).
  • The greatest improvement was seen in the most severe patients: 10-day recovery for RDV plus baricitinib compared with 18-day recovery for control group (Figure).

Methods: Double-blind, randomized, placebo-controlled trial (1:1 ratio) among 1033 patients across 8 countries. Patients were evaluated daily during hospitalization for 28 days. The primary outcome was time to recovery and the secondary outcome was status at day 15. Limitations: Unclear if benefits of baricitinib will be seen in patients receiving glucocorticoids

Implications: This study shows the data used by the FDA to grant an EUAexternal icon for this treatment regimen on November 19, 2020.


Note: Adapted from Kalil et al. Kaplan–Meier estimates of cumulative recovery across 28 days of the overall study population (A) and patients with severe COVID-19 receiving high-flow oxygen or noninvasive ventilation (B). RDV- remdesivir; shaded areas- 95% CI. From Kalil. Baricitinib plus remdesivir for hospitalized adults with COVID-19. NEJM. Copyright © 2020 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.    

Social, Behavioral, and Communication Science


Emergency preparedness and risk communication among African American churches: Leveraging a community-based participatory research partnership COVID-19 initiative. Brewer et al. Preventing Chronic Disease (December 10, 2020).

The Fostering African American Improvement in Total Health (FAITH!) program is a partnership between the Mayo Clinic and 120 African American churches in the Minneapolis-St. Paul area. This article describes their community outreach efforts during the COVID-19 pandemic.

Key findings:

  • Of 120 church leaders contacted, 32 (27%) responded to an emergency preparedness needs assessment and received an emergency preparedness kit.
  • Social media engagement increased 8-fold in the first 7 weeks after implementation of COVID-19 community mitigation measures (Figure).
  • Church leaders identified joint publications from the FAITH!/Mayo Clinic (n = 8), briefings by the Minnesota Governor (n = 8), and briefings by CDC (n = 7) as the most useful and reliable sources of information related to COVID-19.

Methods: In March 2020 a FAITH! COVID-19 Task Force was formed to develop emergency community preparedness plans. Task Force members disseminated emergency preparedness manuals, sent 230 email messages, and posted informative content on social media from April 3 to May 31, 2020. Evaluation looked at reach and engagement measured by unique persons viewing posts (“accessions”) or engaging in posts (with clicks, likes, etc.). Limitations: Generalizability to communities with less internet access.

Implications: Engaging trusted community leaders to create and deliver understandable messages could increase message visibility and adoption of recommendations in the event of an emergency such as the COVID-19 pandemic.


Note: Adapted from Brewer et al. Facebook participation metrics of FAITH! COVID-19 Task Force’s weekly postings of emergency risk management messages during this 8-week project. Reach described the number of unique accessions of the posting while engagement refers to the number of unique interactions. Open access journal; all content freely available.

SARS-CoV-2 Vaccine Acceptance

High vaccine acceptance across society is crucial to attain coverage that would arrest transmission of SARS-CoV-2. Promoting acceptance requires identifying and reaching communities reluctant to vaccinate.


A. International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples.external icon Robinson et al. medRxiv (December 3, 2020).

Key findings:

  • The general populations of 13 countries became less likely to vaccinate against SARS-CoV-2 from March to October 2020 (Figure).
    • From March to May 2020, 79% of respondents intended to vaccinate and 12% intended to refuse.
    • From June to October 2020, 60% of respondents intended to vaccinate and 20% intended to refuse.
  • In the US, females, younger groups, people with lower income or education levels, and members of minority communities were less likely to vaccinate against SARS-CoV-2.

Methods: Nationally representative surveys including a question about intention or willingness to vaccinate were selected from databases for a systematic meta-analysis. 28 eligible articles from January to November 2020 captured 58,656 respondents from 13 countries. Limitations: Results largely relevant for North American and European populations.


Note: Adapted from Robinson et al. Proportion of populations intending to vaccinate by country and time in US or non-US settings. Licensed under CC-BY.

B. Intention of health care workers to accept COVID-19 vaccination and related factors: A systematic review and meta-analysis.external icon Galanis et al. medRxiv (December 11, 2020).

Key findings:

  • Of 8,847 healthcare workers (HCWs) surveyed across 11 studies, 5,354 (55.9%) indicated they intended to accept vaccination against SARS-CoV-2.
  • Physicians reported greater vaccine acceptance (OR range: 1.59–7.76) in 5 studies compared to other healthcare professionals, such as nurses, paramedical staff, and pharmacists.

Methods: A meta-analysis of 11 studies that examined HCW intentions for vaccination. Eligible studies occurred between February and October 2020 in China, Democratic Republic of Congo, France, Greece, Hong Kong, Malta, Zambia, and the US. Limitations: HCWs may overstate acceptance because of social expectations; all studies were convenience samples; time trends not explored.


Combined implications for two summaries (Robinson et al. & Galanis et al.): Targeted messages, including towards healthcare workers, will be needed to improve acceptance of vaccines.

In Brief

Detection, Burden, and Impact


Natural History of SARS-CoV-2: Spectrum and Clinical Course

Natural History of SARS-CoV-2: Re-infection and Sequelae

Protection: Effectiveness of PPE

Protection: Strategies to Reduce Transmission

Prevention, Mitigation, and Intervention Strategies

Note: Adapted from Buss et al. Population-level antibody levels (negative, intermediate, and high) in Manaus (Brazilian Amazon) and the neighboring city of Sao Paulo over the course of the COVID-19 pandemic. Licensed under CC-BY 4.0.

Disclaimer: The purpose of the CDC COVID-19 Science Update is to share public health articles with public health agencies and departments for informational and educational purposes. Materials listed in this Science Update are selected to provide awareness of relevant public health literature. A material’s inclusion and the material itself provided here in full or in part, does not necessarily represent the views of the U.S. Department of Health and Human Services or the CDC, nor does it necessarily imply endorsement of methods or findings. While much of the COVID-19 literature is open access or otherwise freely available, it is the responsibility of the third-party user to determine whether any intellectual property rights govern the use of materials in this Science Update prior to use or distribution. Findings are based on research available at the time of this publication and may be subject to change.


CDC logo /
Page last reviewed: January 26, 2021, 12:00 AM
Content source: Office of the Chief Science Officer - COVID-19